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Summary
The objective of the present work is to extract lovastatin with minimum impurity by
using supercritical carbon dioxide (SC-CO2). A strain of Aspergillus terreus UV 1617 was
used to produce lovastatin by solid-state fermentation (SSF) on wheat bran as a solid sub-
strate. Extraction of lovastatin and its hydroxy acid form was initially carried out using or-
ganic solvents. Among the different screened solvents, acetonitrile was found to be the
most efficient. SC-CO2 was used for extraction of lovastatin from the dry fermented matter.
The effect of supercritical extraction parameters such as the amount of an in situ pretreat-
ment solvent, temperature, pressure, flow rate and contact time were investigated. The
maximum recovery of lovastatin was obtained with 5 mL of methanol as an in situ pretre-
atment solvent for 1.5 g of solid matrix, flow rate of the supercritical solvent 2 L/min,
temperature 50 °C, and contact time 155 min at a pressure 300 bar. The lovastatin extract
obtained after optimizing the conditions of supercritical fluid extraction was found to have
5-fold more HPLC purity than the organic solvent extract.
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Introduction
Compelling regulations on the use of hazardous,
carcinogenic, or toxic solvents, as well as high energy
costs for solvent regeneration have curtailed the growth
of the natural extract industries. One of the alternative
extraction methodologies is the supercritical fluid ex-
traction (SFE) technique that complies with both the
consumer preference and regulatory control. SFE uses
clean, safe, nonflammable, noncorrosive, nontoxic and
environmentally friendly and nonpolluting solvents that
do not leave behind any harmful residues. Its near-am-
bient critical temperature (31.1 °C), good solvation power,
low viscosity and high diffusivity make it ideally suit-
able for thermolabile natural products especially in food
and pharmaceutical applications. SFE is suitable for ex-
traction of the non-polar compounds having a relative
molecular mass lower than 500 Da (1). There are few
reports on SC-CO2 extraction of microbial metabolites
directly from the fermented biomass such as microbial
lipids from the alga Scenedesmus obliquus (2). Freeze-dry-
ing prior to SFE has been shown to be advantageous for
extraction of lipids from several microbial biomasses.
These include eicosapentaenoic acids (EPA) from the
fungus Saprolegnia costatum (3); from the microalga Skele-
tonema costatum, a marine diatom; from Ochromonas da-
nica, a fresh water phytoflagellate (4); and also from the
fungi of the genus Mortierella (5). There are also reports
on the isolation of carotenoids and chlorophyll a from
Nannochloropsis gaditana and from Synechococcus sp. (6,7).
Recently, griseofulvin extraction from the solid matrix
obtained after solid-state fermentation (SSF) has also
been reported (8).
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Lovastatin, a potent drug for lowering blood choles-
terol, acts by competitively inhibiting the enzyme 3-hy-
droxyl-3-methylglutaryl coenzyme A reductase (HMG-
-CoA), which catalyzes the rate limiting step of choles-
terol biosynthesis (9). It has also been reported as a po-
tential therapeutic agent for suppressing tumor growth
through the inhibition of nonsterol isoprenoid synthesis
(10). Lovastatin is produced by various filamentous fun-
gi such as Aspergillus terreus (9,11), Penicillium citrinum
(12) and Monascus rubber (13). Commercial production of
lovastatin on media optimized by response surface meth-
odology (RSM) is based on batch fermentation using A.
terreus, and most literature deals with this species (14–18).
Szakács et al. (19) reported lovastatin production both by
submerged as well as SSF.
In the fermentation broth, lovastatin is mostly pres-
ent in its hydroxy acid form (lovastatin hydroxy acid or
mevinolinic acid). Lovastatin, a b-hydroxy lactone, is
sparingly soluble in water and soluble in organic sol-
vents, while b-hydroxy acid is water-soluble. There are
few reports on the purification of lovastatin, with most
of available literature being patented. Kumar et al. (20)
patented a purification process for isolation of lovastatin
on large scale (6 to 8500 L) extraction, wherein the acidi-
fied fermentation broth was extracted with toluene. In
another patent (21) the acidified fermentation broth was
extracted with butyl acetate and n-octanol (49:51), or
ethyl acetate and cyclohexane (65:35). Lovastatin is a
slightly non-polar compound with a molecular mass of
404.55 Da, making it amenable to SC-CO2 extraction.
The solubility of the lovastatin in pure CO2 and that
modified with various solvents was investigated by Lar-
son and King (22). Taylor et al. (23) investigated primary
and secondary modifiers for the subcritical extraction of
lovastatin from Mevacor tablets with carbon dioxide.
The present work investigates the potential of SC-CO2
for extraction of lovastatin and its hydroxy acid form di-
rectly from the solid matrix obtained after SSF, and its
comparison with organic solvent extraction.
Materials and Methods
Microorganism
A. terreus UV 1718 is a UV mutant of A. terreus
ATCC 20542, and was a gift from an Indian pharmaceu-
tical company. This strain is one of the mutants from the
strain improvement program of the pharmaceutical com-
pany.
Supercritical CO2 equipment
Laboratory scale supercritical CO2 equipment (Speed
SFE, Applied Separation, USA) was used in the present
study with working conditions identical to those de-
scribed by Saykhedkar and Singhal (8).
SSF for production of lovastatin
Initially, several agro-industrial waste substrates
such as wheat bran, corn hull, rice husk, sugarcane ba-
gasse, orange peel, orange pulp, cotton seed oil cake
and groundnut oil were screened for the production of
lovastatin (results not shown). Wheat bran supported
the highest production of lovastatin, and was therefore
chosen for further study. Fermentation was carried out
with 5 g of wheat bran (0.25–0.45 mm) supplemented
with 1.5 mL of K2HPO4 (1 g/L) and 1.5 mL of a trace ion
solution (MgSO4·7H2O 0.5 g/L, ZnSO4· 4H2O 3.4 mg/L,
NaCl 0.5 g/L, FeSO4·7H2O 5 mg/L, CoCl2·6H2O 2 mg/L
and MnSO4 1.6 mg/L). The inoculum size used was 1
mL (2.5·107 spores/mL) (20 % by volume per mass) and
adjusted to final moisture content of 66.8 % with dis-
tilled water (pH=6). The medium was thoroughly mixed
with sterile glass rod and incubated at 28 °C and 80 %
relative humidity in humidity controlled chamber for 3
days. At the end of the fermentation period, the solid
matrix (comprising the SSF substrate, biomass and the
metabolites under study) was dried in a hot air oven at
50 °C for 48 h. It was then ground in mortar, passed
through a sieve to obtain an average particle size of 263
mm, and stored in a deep freezer (–20 °C) until analysis
of lovastatin.
Organic solvent extraction
For the organic solvent extraction (OSE) of lovasta-
tin, initially various solvents were screened such as ace-
tonitrile, methanol, ethyl acetate, butyl acetate, toluene
and chloroform for maximum recovery of lovastatin.
Acetonitrile gave maximum extraction of both hydroxy
acid and lactone lovastatin. Extraction was carried out
in two stages. In the first step, 40 mL of each organic
solvent were mixed with 1.5 g of solid matrix and so-
nicated for 5 min, followed by incubation at 28 °C, 200
rpm for 2 h. In the second step, the extract was filtered
to separate the biomass, and then centrifuged at 10 000
rpm for 10 min to separate the spores from the extract.
This was confirmed further by five individual extrac-
tions, each carried out in different conical flask with a
fresh sample of solid matrix. Clear extract obtained was
stored in glass bottles at –5 °C until analysis.
Supercritical carbon dioxide extraction
Moisture may inhibit the contact between the ex-
traction fluid and the sample. Thus the removal of mois-
ture by freeze-drying or oven drying is recommended
prior to SFE. CO2 cylinders were supplied by Bombay
Carbon Dioxide Gas Corporation, India. In each experi-
ment, 1.5 g of dried biomass was loaded into a 10- or
100-mL extraction column and 0.5-mm spare filters were
placed at both ends of the extraction column to prevent
the transfer of the particles. The extraction column was
put into the temperature controlled chamber of the
supercritical fluid extractor and equilibrated to a pre-set
extraction temperature. The high pressure pump com-
pressed the CO2 to the desired pre-set pressure. The
supercritical phase at the outlet of the supercritical fluid
extractor was passed though two automatic valves in
which the pressure was reduced slowly via collection
bottle. The temperature of the restrictor valve was kept
10 °C higher than in the extractor chamber. The percent-
age recovery of lovastatin by SFE was optimized by
varying the extraction parameters such as the volume of
an in situ pretreatment solvent (1, 2.5 and 5 mL of meth-
anol), temperatures (40, 50 and 60 °C), pressure (200, 300
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and 400 bar), the flow rate of supercritical solvent (1, 1.5
and 2 L/min) and contact time.
For the SFE extraction without any pretreatment
with methanol, 10-mL extraction vessel was used. The
conditions of extraction were 40 °C, 300 bar at a flow
rate of 2 L/min for 60 min. The size of the sample was
1.5 g, having an average particle size of 263 mm. For the
in situ pretreatment study, a 100-mL vessel was used,
the downstream glass wool of solid matrix was moist-
ened with 1, 2.5 and 5 mL of methanol and the extrac-
tion was carried out using the same operational condi-
tions.
HPLC analysis
Lovastatin was identified by comparison with the
original standard kindly provided by Biocon Ltd, India.
Lovastatin was quantified on an HPLC system (Jasko,
Japan) equipped with a UV detector and a Hamilton C18
column (250´4.6 mm, 5 mm i.d.), and an eluent compris-
ing acetonitrile and 0.1 % phosphoric acid (60:40). The
flow rate used was 1 mL/min and the injection volume
was 20 mL. The chromatogram was recorded at 238 nm.
Data acquisition and analysis were done on PC based
software. For conversion of lovastatin to lovastatin hy-
droxy acid, 20 mg of lovastatin powder were suspended
in 25 mL of methanol and 0.025 M NaOH, and incu-
bated in orbital incubator shaker at 45 °C and 100 rpm
for 30 min. After completion of the reaction, pH of the
solution was adjusted to 7.7 using 0.1 M HCl. A stan-
dard plot was prepared by diluting the above solution.
Lovastatin and the corresponding lovastatin hydro-
xy acid were identified by their retention time. The mass
fractions of lovastatin and lovastatin hydroxy acid were
added and reported as yield. The percentage recovery of
lovastatin was defined as the mass of lovastatin ob-
tained by SC-CO2 extraction per gram of solid matrix di-
vided by the mass of lovastatin obtained by OSE per
gram of solid matrix multiplied by hundred.
Results and Discussion
Organic solvent extraction
In most patents, the acid form of lovastatin has been
converted to the lactone form, and then extracted with
organic solvents. In our work, an attempt was made to
select a solvent that would extract both hydroxy acid
and lactone lovastatin. It was found that acetonitrile
could extract both compounds. This had not been re-
ported earlier. The advantage of this approach is han-
dling smaller volumes for the conversion of acid to
lactone, as compared to that of doing the same in the
fermentation broth. Secondly, being an SSF, the use of
acid catalyst for conversion of acid to lactone would be
very difficult.
Initially, the attempt was made to extract the hydro-
xy acid and lactone form of lovastatin by using various
solvents, both polar and non-polar. It was seen that the
extraction of lovastatin hydroxy acid decreased with a
decrease in the polarity of the organic solvent. Hence,
polar organic solvents like methanol, acetonitrile and
ethyl acetate were found to be more suitable than the
non-polar solvents to extract both the lactone and lova-
statin hydroxy acid. Among the polar solvents, aceto-
nitrile was found to be the most efficient (results not
shown). An average lovastatin content of (1722±50) mg/g
of dried fermented matter was obtained.
Supercritical carbon dioxide extraction
Effect of methanol as an in situ pretreatment solvent
In the initial study, the SC-CO2 was used in SFE
without any pretreatment with methanol in a 10-mL
sample vessel under the conditions indicated in the Ma-
terials and Methods section. The percentage recovery of
lovastatin was very low, at 17.5 %. This result was in ac-
cordance with Larson and King (22), who reported the
solubility of lovastatin to be very low in SC-CO2 as com-
pared to the methanol modified SC-CO2.
According to Larson and King (22), the co-solvent
can be introduced into the system in two ways. In the
first method, glass wool placed up-steam of the solid
sample in the extractor is moistened with another solvent
(methanol) so that the SC-CO2 is modified as it passes
through the glass wool, and the modified SC-CO2 then
passes through the solute bed. This type of solvent is
also called entrained solvent. In the second method, CO2
and the solvent are pre-mixed at a specific concentra-
tion. Due to the lower percentage recovery of lovastatin
by SC-CO2 in the absence of any solvent, methanol was
used as an in situ pretreatment solvent with pure CO2.
For the addition of methanol to the extraction vessel, the
methodology of filling the sample and glass wool in the
extraction vessel was changed, as shown in Fig. 1.















Fig. 1. Modification of the filling strategy of SC-CO2 extraction
vessel
The percentage recovery of lovastatin increased with
an increase in the volume of methanol (Fig. 2). The high-
est percentage recovery of 58.11 % was obtained using
5 mL of methanol with a batch size of 1.5 g of solid ma-
trix. A further increase in methanol was difficult to han-
dle, and hence all further studies were done with 5 mL
of methanol as an in situ pretreatment solvent.
Effect of temperature
Using SC-CO2 modified with 5 mL of methanol as
an in situ pretreatment solvent, the effect of temperature
with respect to pressure on percentage recovery was in-
vestigated. All experiments were conducted at constant
flow rate of 2 L/min using dried solid matrix with aver-
age particle diameter of 263 mm. The results are shown
in Figs. 3a-c. It is evident that the effect of the changes
in temperature and pressure on the percentage recovery
was not uniform. The mass fractions of lovastatin ob-
tained at 200 bar after 55 min of extraction were 648.99,
1373.58 and 659.24 mg/g at 40, 50 and 60 °C, respec-
tively. The percentage recovery increased from 37.69 to
79.78 % when temperature increased from 40 to 50 °C,
and it again decreased from 79.78 to 38.29 % with fur-
ther increase in temperature from 50 to 60 °C.
The percentage recovery of lovastatin at 300 bar and
temperature of 40–60 °C is shown in Fig. 3b. The pattern
of extraction was similar as at 200 bar. The mass frac-
tions of the obtained lovastatin were 948.69, 1472.67 and
949.11 mg/g at 40, 50 and 60 °C, respectively after 55
min of extraction. Here, the percentage recovery in-
creased from 55.1 to 85.53 % when temperature was in-
creased from 40 to 50 °C, and it again decreased from
85.53 to 55.12 % when temperature was further increased
from 50 to 60 °C. The initial percentage recovery up to
35 min at 50 °C was 70.28 %. Further increase in time to
55 min increased it to 85.53 %. This might be due to suf-
ficient amount of methanol available with SC-CO2 for
extraction of lovastatin initially, but after some time me-
thanol may have been exhausted from the glass wool,
and during that period only CO2 might have been avail-
able for extraction.
The percentage recovery of lovastatin as a function
of temperature at 400 bar is shown in Fig. 3c. The mass
fractions of the obtained lovastatin were 1245.32, 1136.45
and 1064.86 mg/g at 40, 50 and 60 °C, respectively after
55 min of contact time. The percentage recovery in-
creased from 61.84 to 72.33 % when temperature was
decreased from 60 to 40 °C. This could be due to an in-
crease in the solvent density with the decrease of tem-
perature. At 400 bar, the highest percentage recovery ob-
tained was 72.33 % at 40 °C.
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Fig. 2. Effect of methanol as an in situ pretreatment solvent on












































































Fig. 3. Effect of temperature on the percentage recovery of lova-
statin from solid matrix after SSF at a) 200 bar, b) 300 bar and c)
400 bar
In general, the extractability of the compounds with
SC-CO2 depends on the occurrence of individual func-
tional groups in these compounds, the molecular mass,
and polarity. The solubility of the compounds therein is
strongly influenced by temperature, pressure and entrain-
er (22). In this study, percentage recovery of lovastatin
was higher at 300 bar and 50 °C as compared to other
conditions of extraction used in the study.
Effect of pressure
The second stage of SC-CO2 experiments was car-
ried out at constant temperature of 50 °C, constant flow
rate of 2 L/min and pressures of 200, 300 and 400 bar
for varying time periods ranging from 20 to 55 min
using dried solid matrix with average particle diameter
of 263 mm. The results indicate the percentage recovery
to increase with an increase in pressure from 200 to 300
bar. The obtained mass fractions of lovastatin were
1373.58 and 1472.67 mg/g at 200 and 300 bar, respec-
tively after 55 min of contact time (Fig. 4). This phenom-
enon is well known and explained by the fact that an in-
crease in pressure increases the density of supercritical
CO2, resulting in an increase in the solvation power. The
percentage recovery ranged from 79.78 to 85.53 with an
increase in pressure from 200 to 300 bar, which could be
attributed to a corresponding increase in the density of
the supercritical fluid. Fig. 4 also shows that an increase
in pressure from 300 to 400 bar decreased the percentage
recovery, indicating an optimum extraction pressure to
exist around 300 bar. The obtained mass fractions of
lovastatin were 1472.67 and 1136.45 mg/g at 300 and 400
bar, respectively. This could be explained by the fact that
an increase in the pressure decreases the diffusivity. In
addition, an increase in the pressure causes the solid
matrix to become more packed, and thereby decreases
the void fraction.
Effect of supercritical CO2 flow rate
These experiments were carried out with 5 mL of
methanol as an in situ pretreatment solvent, constant
temperature of 50 °C, constant pressure of 300 bar at
SC-CO2 flow rates of 1, 1.5 and 2 L/min, using dried
solid matrix with average particle diameter of 263 mm.
Fig. 5 shows the effect of SC-CO2 flow rate on the per-
centage recovery of lovastatin as a function of flow rate
and contact time varying from 20 to 55 min. The ob-
tained mass fractions of lovastatin were 1403.66, 1434.33
and 1472.66 mg/g at flow rates of 1, 1.5 and 2 L/min, re-
spectively after 55 min. The increase in flow rate from 1
to 2 L/min increased the percentage recovery only mar-
ginally from 81.52 to 85.53 %. This could be due to the
fact that all experiments were done at a flow rate that
was already high. Hence, further significant increase in
extractability was not observed with an increase in the
flow rate.
Effect of contact time
Final stages of SC-CO2 experiments were carried out
for maximum lovastatin recovery at optimum SC-CO2 con-
ditions, which were established as a temperature of 50
°C, a pressure of 300 bar, a flow rate of 2 L/min and av-
erage particle diameter of 263 mm. Fig. 6 shows the ef-
fect of contact time on the percentage recovery of lova-
statin from the SSF matrix powder. Recovery of 97.38 %
was obtained after 155 min of contact time. It was also
observed that almost 90.8 % of lovastatin were recov-
ered in the first 75 min. The small percentage recovery
at a later stage indicates that there might be no extrac-
table lovastatin available for SC-CO2, possibly due to
strong interaction between the matrix and lovastatin. A

























Fig. 4. Effect of pressure on the percentage recovery of lovasta-

























Fig. 5. Effect of the flow rate of SC-CO2 on the percentage reco-






















Fig. 6. Effect of contact time on the percentage recovery of lova-
statin from solid matrix after SSF
report by Manzoni et al. (15) suggests that 83 % lova-
statin is associated with the mycelium, and 17 % is free
in the culture filtrate.
The extract obtained after SC-CO2 was compared
with that obtained by OSE. The SFE extract had 45–50 %
HPLC purity of lovastatin as compared to the OSE ex-
tract, which had 10–15 % HPLC purity. The OSE extract
was dark yellowish and brown in colour, while that of
SC-CO2 was pale yellow. This indicated the selectivity of
the SC-CO2 towards the non-polar compounds. Fig. 7
shows the superimposed chromatogram of the OSE ex-
tract and that of SFE extract obtained under the opti-
mized conditions of SFE. The higher purity of SFE extract
eases further purification of lovastatin, and in addition
requires far less solvents as compared to conventional
method of extraction and purification.
This study is the first of its kind for extraction of
lovastatin directly from the solid matrix obtained after
SSF that contains the biomass as well as the metabolite.
There are reports on SFE of pure lovastatin to compute
the solubility parameters (23), and SFE of lovastatin
from Mevacor tablets (22), but none on downstream
processing or on the solid matrix obtained after SSF.
Conclusions
SSF for the production of lovastatin is a viable com-
mercial alternative to submerged fermentation, but it re-
quires a different strategy for downstream processing.
This work brings the potential of supercritical carbon di-
oxide extraction for isolation of lovastatin with lesser
impurity directly from the solid matrix obtained after
SSF.
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